A total of 172,682 diabetic patients who were diagnosed with COVID-19 were included in the analysis of MACCEs, among which 11,516 patients were prescribed SGLT2 inhibitors during the last six months before COVID-19 diagnosis, and 161,166 patients were not prescribed SGLT inhibitor (Figure 1). This evidence concerns the gene SLC5A2 and COVID-19.